Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias

George H. Crossley MD1 | Luigi Padeletti (deceased) MD2 | Steven Zweibel MD3 | J. Harrison Hudnall BS4 | Yan Zhang MS4 | Giuseppe Boriani MD, PhD5

1Vanderbilt Heart and Vascular Institute, Nashville, Tennessee
2Cardiology Department, I.R.C.C.S. MultiMedica, Sesto San Giovanni, Milano, Italy
3Hartford Healthcare Heart and Vascular Institute, Hartford Hospital, Hartford, Connecticut
4Medtronic plc, Mounds View, Minnesota
5Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena University Hospital, Modena, Italy

Abstract

Background: Reactive atrial-based antitachycardia pacing (rATP) aims to terminate atrial tachyarrhythmia/atrial fibrillation (AT/AF) episodes when they spontaneously organize to atrial flutter or atrial tachycardia; however, its effectiveness in the real-world has not been studied. We used a large device database (Medtronic CareLink, Medtronic, Minneapolis, MN, USA) to evaluate the effects of rATP at reducing AT/AF.

Methods: Pacemaker, defibrillator, and resynchronization device transmission data were analyzed. Eligible patients had device detected AT/AF during a baseline period but were not in persistent AT/AF immediately preceding first transmission. Note that 1:1 individual matching between groups was conducted using age, sex, device type, pacing mode, AT/AF, and percent ventricular pacing at baseline. Risks of AT/AF events were compared between patients with rATP-enabled versus control patients with rATP-disabled or not available in the device. For matched patients, AT/AF event rates at 2 years were estimated by Kaplan-Meier method, and hazard ratios (HRs) were calculated by Cox proportional hazard models.

Results: Of 43,440 qualifying patients, 4,203 had rATP on. Matching resulted in 4,016 pairs, totaling 8,032 patients for analysis. The rATP group experienced significantly lower risks of AT/AF events lasting ≥1 day (HR 0.81), ≥7 days (HR 0.64), and ≥30 days (HR 0.56) compared to control (P < 0.0001 for all). In subgroup analysis, rATP was associated with reduced risks of AT/AF events across age, sex, device type, baseline AT/AF, and preventive atrial pacing.

Conclusions: Among real-world patients from a large device database, rATP therapy was significantly associated with a reduced risk of AT/AF. This association was independent of whether the patient had a pacemaker, defibrillator, or resynchronization device.

KEYWORDS

atrial fibrillation, atrial flutter, atrial tachycardia, defibrillator, pacemaker, pacing, reactive ATP, resynchronization

1 | INTRODUCTION

Atrial fibrillation (AF) is the most prevalent heart rhythm disorder with approximately 5.1 million lives being affected in the United States.1 Prevalence varies by age, with an approximate 5% increase in risk per year above the age of 652 and by sex, with 60% being male.3 Although many episodes are asymptomatic, AF is associated with poor quality of life and increased risks of heart failure, dementia, stroke, and death.4–6 Costs of AF to the United States healthcare system total $26 billion annually, and the incremental cost for a single patient is $8,705.7 As the disease progresses to persistent episodes and to a permanent condition, symptoms worsen, comorbidities become more prevalent, and risks of thromboembolism, acute heart failure decompensation, and death increase.3,5
AF is irregular, typically originates from the pulmonary veins, and, as such, requires cardioversion to terminate persistent episodes. AF is not susceptible to pace-termination; however, slower organized rhythms such as atrial flutter or atrial tachycardia can often be terminated by antitachycardia pacing (ATP). Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF. Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF.9 Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF.9 Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF.9 Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF.9 Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF.9 Reactive atrial tachyarrhythmia (AT/AF) episodes can spontaneously transition between AF and atrial flutter/tachycardia, even in patients with chronic AF.

Study design and database

Thus, adjudication of AT/AF endpoints is essential to assess the effectiveness of rATP therapy at reducing occurrence of AT/AF and subsequently preventing progression of AT/AF in patients with pacemakers or persistent AT/AF were associated with a lower incidence of progression to persistent and permanent AF. In addition, use of rATP reduced early recurrence of AF and was associated with more frequent positive atrial remodeling (>10% reduction in left atrial diameter). AF-related hospitalization, AF-related emergency department visits, and cardioversions were also significantly reduced. However, MINERVA’s population was limited to pacemaker recipients without complete atrioventricular block. Thus, we set out to study the real-world effectiveness of rATP at reducing AT/AF occurrence and subsequently preventing AT/AF progression in patients with pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization (CRT) devices using a large nationwide device database.

2 METHODS

2.1 Study design and database

The study was a retrospective cohort assessment designed to evaluate the effectiveness of rATP therapy at reducing occurrence of AT/AF and subsequently preventing progression of AT/AF in patients with pacemakers, ICDs, and CRT devices. Risks of paroxysmal, persistent, and longstanding-persistent AT/AF events based on device detected daily AT/AF burden were compared between patients with rATP-enabled versus patients with rATP-disabled or not available in the device. Transmission data were extracted from the deidentified CareLink database on August 23, 2016. The database stores pacemaker, ICD, CRT-defibrillator, and CRT-pacemaker data transmitted via the Medtronic remote monitoring server and includes data on patient age, sex, implant date, device make and model, and data parameters (e.g., rATP, pacing mode, preventive atrial pacing), and diagnostics and episodes from the device. Diagnostic data used in this study were daily AT/AF burden and percentage ventricular pacing (VP). These data were continuous as the devices maintain up to 14 months of storage capacity. The device-reported AT/AF burden is determined in a consistent manner across devices and is highly accurate, where appropriate detection of AT/AF episodes and duration sensitivity are >95%, regardless of right atrial lead position. Thus, adjudication of AT/AF episodes was deemed unnecessary. The CareLink database does not collect clinical parameters outside of the aforementioned items (e.g., medications, comorbidities, treatments, outcomes).

2.2 Patients

Patients were ≥18 years old and implanted with dual-chamber pacemakers, dual-chamber ICDs, CRT-pacemakers, and CRT-defibrillators. Devices implanted from January 1, 2012 or later were included, and only data from the patient’s first device was used. The date of first CareLink transmission is called Day 0. We use “the first transmission” and “Day 0” interchangeably in this report. In an effort to align with the MINERVA design, eligible patients had a history of AT/AF at baseline but were not in persistent AT/AF immediately preceding Day 0. Specifically, patients had to have at least one day with 5 minutes or more of AT/AF during the baseline period of up to 1 year preceding Day 0 but were excluded if they had >23 hours of AT/AF consecutively from Day minus 7 through Day 0. Further, eligible patients had to have transmitted data beyond Day 0 for up to 2 years. Patients were identified as a rATP subject if they had the rATP feature turned on for all transmissions, or they were identified as the control subjects if they had rATP off for all transmissions or were implanted with devices not capable of delivering atrial-ATP.

To control for imbalances between the two groups, we performed individual matching using baseline data that are known risk factors for AT/AF development. Patients were matched 1:1 for age, sex, device type, pacing mode, percentage VP, and AT/AF at baseline. Patients implanted with CRT devices were also matched on programming of the AdaptivCRT feature.

2.3 Mechanism of rATP

The rATP feature is a second-generation algorithm designed to opportunistically terminate AT/AF rhythms when they spontaneously organize to atrial flutter or to an atrial tachycardia, even in persistent episodes. Upon detection of an AT/AF episode, the device monitors rhythm transitions based on regions of atrial cycle lengths and regularity. Up to three ATP pacing therapies (Ramp or Burst+) are delivered for each region that the episode may transition to. Cycle length regions are 50-ms wide for regular rhythms and 100–150-ms wide for irregular rhythms. Furthermore, if the AT/AF episode persists, a time interval feature allows for counters to reset; thus, ATP may be reapplied at programmable durations (e.g., every 7 hours). While we acknowledge that ATP cannot terminate true AF, the strength of the algorithm lies in its ability to redeliver ATP when it detects a change in the patient’s rhythm to a moment when the rhythm might be more vulnerable to termination with ATP (e.g., atrial flutter). Performance of rATP, as reported by Padeletti et al., demonstrated a median efficacy of 44.4%, which was higher in episodes of long cycle length and regular rhythm and in episodes with many rhythm transitions.

2.4 Endpoints

The aim of the study was to demonstrate that rATP was associated with a lower risk of AT/AF events, including paroxysmal, persistent, and longstanding-persistent AT/AF. We used the same AT/AF endpoints from the randomized MINERVA trial. They were time to first AT/AF event lasting ≥1 day (paroxysmal), ≥7 consecutive days
(persistent), and ≥30 consecutive days (longstanding-persistent). All the AT/AF events were based on device-detected daily AT/AF burden. In addition, days with >23 hours of AT/AF burden were counted and classified within every 30 days from Day minus 30 to up to 2 years of follow-up, and the effects of rATP on this longitudinal discrete endpoint were evaluated. ATP efficacy was also determined in the rATP group using AT/AF episode data.

2.5 | Statistical analysis

Individual matching was conducted through a Greedy algorithm. This process ensured that, for each rATP subject, the matched control had exactly the same values for categorical matching variables (sex, device type, pacing mode, AT/AF up to 1 year preceding Day 0, and AdaptivCRT) and was within the matching margins for continuous matching variables (age and percentage VP). Details of matching variables can be found in the Supplementary Material.

Primary analyses of study endpoints focused on the matched subjects. Time to an event started from Day 0 and ended at the date that the event occurred the first time for subjects who experienced such an event or the date of last documented daily AT/AF record during up to 2 years of follow-up for those who did not experience such an event. For events lasting more than one day, the first day was used as the date of occurrence. Event rates at 2 years were estimated by Kaplan-Meier method.

Effects of rATP on each time-to-event endpoint were evaluated using Cox proportional hazard models. Covariates considered in the models were group, age (<65 and ≥65 years), sex, device type, AT/AF during a baseline period of up to 1 year preceding Day 0, duration from implant to Day 0 (≤5 and >5 months), AT/AF burden from Day minus 30 to Day 0, and programming status of preventive atrial pacing therapies including atrial preference pacing (APP), atrial rate stabilization (ARS), and postmode switch overdrive pacing (PMOP) at Day 0. The last three sets of covariates were included to adjust for the differences in them between rATP and control subjects after the matching. Final models were determined using a backward selection method.

The incidence of AT/AF events were significantly reduced in the rATP group compared to control after controlling for other covariates in the main effect Cox models (P < 0.001 for all, Table 2). Specifically, in each group, patients were mostly male (59.0%) and on average 73 years of age; 69.1%, 13.2%, and 17.7% had pacemakers, ICDs, and CRTs, respectively; 64.8% had MVP/R pacing mode at the first transmission. Among CRT patients, 57.5% did not have the AdaptivCRT feature available, 10.3% had Adaptive BiV, 21.4% had Adaptive BiV and LV, and 10.8% had Non-Adaptive BiV (not shown in Table 1). During the up to 1-year baseline period that preceded the first transmission, 7.9% and 7.5% of patients had >23 hours of daily AT/AF burden lasting for at least 7 and 30 consecutive days, respectively. Differences after matching were observed in the AT/AF burden from Day minus 30 to Day 0 (87.8% rATP vs 75.8% in the control group). Relative to control, a larger proportion of rATP patients were implanted with a pacemaker and had their device programmed to MVP mode. The 1:1 individual matching resulted in 4,016 pairs, bringing the total number of subjects to 8,032 for the primary analyses.

The individual matching resulted in nearly identical characteristics of matching factors between the matched patient groups (Table 1). Specifically, in each group, patients were mostly male (59.0%) and on average 73 years of age; 69.1%, 13.2%, and 17.7% had pacemakers, ICDs, and CRTs, respectively; 64.8% had MVP/R pacing mode at the first transmission. Among CRT patients, 57.5% did not have the AdaptivCRT feature available, 10.3% had Adaptive BiV, 21.4% had Adaptive BiV and LV, and 10.8% had Non-Adaptive BiV (not shown in Table 1). During the up to 1-year baseline period that preceded the first transmission, 7.9% and 7.5% of patients had >23 hours of daily AT/AF burden lasting for at least 7 and 30 consecutive days, respectively. Differences after matching were observed in the AT/AF burden from Day minus 30 to Day 0 (87.8% rATP vs 85.1% control with 0 days of >23 hours of AT/AF burden), duration from implant to Day 0 (median: 5.9 and 4.3 months in rATP and control subjects, respectively), and preventive atrial pacing therapies at Day 0 (9.3%, 9.7%, and 15.9% in rATP subjects vs 2.7%, 2.0%, and 8.3% in control subjects with APP, ARS, and PMOP being programmed on, respectively).

3 | RESULTS

3.1 | Patients

There were 43,440 patients from 3,439 centers who met eligibility criteria (Supplementary Figure S1). Most were from centers in the United States (42,765, 98.4%), and the rest were from centers in Australia (632, 1.5%) and New Zealand (33, 0.08%), and unknown (10, 0.02%). rATP was enabled in 4,203 (9.7%) of the patients.

Baseline characteristics that were considered in the individual matching are shown in Table 1. As expected, in the full cohort of 43,440 patients, rATP patients had more AT/AF at baseline. For example, 85.8% of rATP patients had at least one day with an hour or more of AT/AF versus 75.8% in the control group. Relative to control, a larger proportion of rATP patients were implanted with a pacemaker and had their device programmed to MVP mode. The 1:1 individual matching resulted in 4,016 pairs, bringing the total number of subjects to 8,032 for the primary analyses.

The individual matching resulted in nearly identical characteristics of matching factors between the matched patient groups (Table 1). Specifically, in each group, patients were mostly male (59.0%) and on average 73 years of age; 69.1%, 13.2%, and 17.7% had pacemakers, ICDs, and CRTs, respectively; 64.8% had MVP/R pacing mode at the first transmission. Among CRT patients, 57.5% did not have the AdaptivCRT feature available, 10.3% had Adaptive BiV, 21.4% had Adaptive BiV and LV, and 10.8% had Non-Adaptive BiV (not shown in Table 1). During the up to 1-year baseline period that preceded the first transmission, 7.9% and 7.5% of patients had >23 hours of daily AT/AF burden lasting for at least 7 and 30 consecutive days, respectively. Differences after matching were observed in the AT/AF burden from Day minus 30 to Day 0 (87.8% rATP vs 85.1% control with 0 days of >23 hours of AT/AF burden), duration from implant to Day 0 (median: 5.9 and 4.3 months in rATP and control subjects, respectively), and preventive atrial pacing therapies at Day 0 (9.3%, 9.7%, and 15.9% in rATP subjects vs 2.7%, 2.0%, and 8.3% in control subjects with APP, ARS, and PMOP being programmed on, respectively).

3.2 | Time to AT/AF events

The incidence of AT/AF events were significantly reduced in the rATP group compared to control after controlling for other covariates in the main effect Cox models (P < 0.0001 for all, Table 2). Specifically, patients with rATP were 19% less likely to have an AT/AF event lasting ≥1 day (HR: 0.81; 95% confidence interval [CI], 0.74–0.88), 36% less likely to have an AT/AF event lasting ≥7 days (HR: 0.64; 95% CI, 0.57–0.73), and 44% less likely to have an AT/AF events lasting ≥30 days...
TABLE 1  Characteristics of the patients at baseline

| Variable                  | Full cohort (N = 43,440) | Reactive ATP group (N = 4,203) | Control group (N = 39,237) | Matched cohort (N = 8,032) | Reactive ATP group (N = 4,016) | Control group (N = 4,016) |
|---------------------------|--------------------------|--------------------------------|-----------------------------|-----------------------------|--------------------------------|-----------------------------|
| Age – years               | 73.0 ± 11.0              | 71.8 ± 11.5                    | 73.4 ± 10.5                 | 73.4 ± 10.5                 | 73.4 ± 10.5                    | 73.4 ± 10.5                 |
| Male sex – no. (%)        | 2,476 (58.9%)            | 24,442 (62.3%)                 | 2,370 (59.0%)               | 2,370 (59.0%)               | 2,370 (59.0%)                  | 2,370 (59.0%)               |
| Device type – no. (%)     |                          |                                |                             |                             |                                |                             |
| Pacemaker                 | 2,852 (67.9%)            | 23,688 (60.4%)                 | 2,775 (69.1%)               | 2,775 (69.1%)               | 2,775 (69.1%)                  | 2,775 (69.1%)               |
| ICD                       | 578 (13.8%)              | 6,287 (16.0%)                  | 531 (13.2%)                 | 531 (13.2%)                 | 531 (13.2%)                    | 531 (13.2%)                 |
| CRT†                      | 773 (18.4%)              | 9,262 (23.6%)                  | 710 (17.7%)                 | 710 (17.7%)                 | 710 (17.7%)                    | 710 (17.7%)                 |
| Pacing mode – no. (%)     |                          |                                |                             |                             |                                |                             |
| DDD/R                     | 1,514 (36.0%)            | 18,087 (46.1%)                 | 1,408 (35.1%)               | 1,408 (35.1%)               | 1,408 (35.1%)                  | 1,408 (35.1%)               |
| DDI/R                     | 24 (0.6%)                | 427 (1.1%)                     | 6 (0.2%)                    | 6 (0.2%)                    | 6 (0.2%)                       | 6 (0.2%)                    |
| MVP/R                     | 2,664 (63.4%)            | 20,714 (52.8%)                 | 2,602 (64.8%)               | 2,602 (64.8%)               | 2,602 (64.8%)                  | 2,602 (64.8%)               |
| AAI/R                     | 1 (0.02%)                | 9 (0.02%)                      | 0 (0.0%)                    | 0 (0.0%)                    | 0 (0.0%)                       | 0 (0.0%)                    |
| AT/AF up to one year preceding Day 0 – no. (%)‡ | 596 (14.2%) | 9,483 (24.2%) | 570 (14.2%) | 570 (14.2%) | 570 (14.2%) | 570 (14.2%) |
| Ventricular pacing - % §  |                          |                                |                             |                             |                                |                             |
| Pacemaker                 | 26.3 ± 39.2              | 34.5 ± 42.2                    | 25.6 ± 39.2                 | 25.6 ± 39.2                 | 25.6 ± 39.2                    | 25.6 ± 39.2                 |
| ICD                       | 16.4 ± 32.3              | 15.1 ± 30.6                    | 13.1 ± 30.0                 | 13.1 ± 30.0                 | 13.0 ± 30.1                    | 13.0 ± 30.1                 |
| CRT                       | 94.6 ± 14.2              | 92.5 ± 15.8                    | 96.4 ± 9.4                  | 96.5 ± 9.4                  | 96.5 ± 9.4                     | 96.5 ± 9.4                  |

* Data at first transmission (Day 0). Plus-minus values are means ± standard deviation.
† With or without defibrillator.
‡ From device data up to 12 months preceding Day 0.
§ From device data up to 30 days preceding Day 0.
AT/AF = atrial tachyarrhythmia; ATP = antitachycardia pacing; CRT = cardiac resynchronization therapy; ICD = implantable cardioverter defibrillator.

TABLE 2  Risks of AT/AF between matched patient groups (N = 8,032)

| Event                      | Number of subjects with event (2-year Kaplan-Meier event rate) | Cox proportional hazard model† | Frailty model† |
|----------------------------|-----------------------------------------------------------------|--------------------------------|---------------|
| AT/AF ≥1 day               | 1,123 (38.4%)                                                   | Hazard ratio (95% CI)          | Hazard ratio (95% CI) |
|                            | Reactive ATP group (N = 4,016)                                  | 0.81 (0.74–0.88)              | 0.79 (0.72–0.87) |
|                            | Control group (N = 4,016)                                       | P-value <0.0001               | P-value <0.0001 |
| AT/AF ≥7 days              | 537 (20.4%)                                                     | 0.64 (0.57–0.73)              | 0.62 (0.55–0.71) |
|                            | Reactive ATP group (N = 4,016)                                  | P-value <0.0001               | P-value <0.0001 |
|                            | Control group (N = 4,016)                                       |                                |               |
| AT/AF ≥30 days             | 306 (12.2%)                                                     | 0.56 (0.48–0.66)              | 0.54 (0.46–0.64) |
|                            | Reactive ATP group (N = 4,016)                                  | P-value <0.0001               | P-value <0.0001 |
|                            | Control group (N = 4,016)                                       |                                |               |

† Model contains main effects only: group, age, sex, device type, AT/AF up to 1 year preceding Day 0, duration from implant to Day 0, AT/AF from Day minus 30 to Day 0, and other atrial therapies (APP, ARS, and PMOP) on Day 0. AT/AF = atrial tachyarrhythmia; ATP = antitachycardia pacing; CI = confidence interval.

(HR: 0.56; 95% CI, 0.48–0.68). The frailty model results were consistent with those from Cox proportional hazard models (P < 0.0001 for all, Table 2). In the final Cox models, rATP effect remained highly significantly (P < 0.0001 for all, data not shown), while ARS and PMOP were not significant and hence removed from the final models and APP was slightly significant only in the final model for AF/AF lasting ≥1 day (P = 0.0469, data not shown).

Patients with rATP had an absolute reduction in the rates of AT/AF events lasting ≥1 day, ≥7 days, and ≥30 days at 2 years by 4.6%, 8.5%, and 7.9%, respectively. In Figure 1, the Kaplan-Meier curves show a reduced risk of AT/AF ≥7 days in the rATP group immediately at Day 1, and the effects continued to progress out to 2 years.

Subgroup analyses were conducted to assess the effects of rATP on the risks of ≥1, ≥7, and ≥30 days of AT/AF across age, sex, device type, baseline AT/AF, and preventive atrial pacing at baseline. Figure 2 is the forest plot demonstrating that rATP was associated with reduced risk of ≥7 days of AT/AF for most subgroups. The 1-day (Supplementary
The hazard ratio of 0.64 (95% CI, 0.57–0.73) indicates a 36% decrease in the risk of having persistent AF among patients with rATP therapy on as compared to control. AT/AF = atrial tachyarrhythmia; CI = confidence interval; rATP = reactive atrial-based antitachycardia pacing [Color figure can be viewed at wileyonlinelibrary.com]

Figure S2 and 30-day (Supplementary Figure S3) data are seen in the Supplementary Material. None of the interactions between group and individual factors was significant. Particularly, effects were consistent across pacemakers, ICDs, and CRT devices with the rATP group experiencing significantly reduced risks of having AT/AF events. For example, the risk of developing ≥7 days of AT/AF was significantly lower in rATP patients with pacemakers (HR: 0.64; 95% CI, 0.55–0.74), ICDs (HR: 0.58; 95% CI, 0.43–0.77), and CRT devices (HR: 0.73; 95% CI, 0.57–0.93). Significant rATP effects on the risk reduction of AT/AF events were also independent of APP, ARS, and PMOP being programmed on or not at the first transmission. Detailed results of the subgroups analysis for both the Cox proportional hazard and frailty models can be viewed in the Supplementary Material.

Cox regression analyses were also performed among the full cohort of 43,440 eligible patients, considering the same set of covariates as for the matched cohort. It was demonstrated in the main effect models that rATP was associated with significant reductions in AT/AF events lasting ≥1 day, ≥7 days, and ≥30 days (P < 0.0001 for all, Supplementary Table S4).

3.3 | AT/AF burden within every 30 days over time

Stacked bar charts in Figure 3 show that the percentage of having zero days of > 23 hours of AT/AF in month 0 (i.e., within 30 days before the first transmission) was slightly higher in the rATP group (87.8%, 3,525/4,016) compared to the control group (85.1%). For this reason, we controlled for the AT/AF burden from Day minus 30 to Day 0 in the Cox and frailty models for time-to-event endpoints. The bar charts also show the percentage of rATP patients having 30 days of > 23 hours of AT/AF within every 30 days from the first transmission to the end of 2 years of follow-up was much lower than that of control patients. This difference was proven to be statistically significant in the GEE analysis. Specifically, when only considering time and group in the model, rATP patients were significantly less likely to have higher levels of AT/AF burden over time (risk ratio: 0.64, 95% CI: 0.57–0.73). After adjusting for all the covariates, the association of rATP with reduced risk of having higher levels of AT/AF burden was significant for all the categories of AT/AF burden throughout the follow-up period except the lowest category (≥5 minutes but <1 hour, P = 0.9570).

3.4 | ATP efficacy

In the rATP group, 198,838 out of 451,235 (44.1%) AT/AF episodes were terminated successfully by the last AT/AF therapy; the GEE estimated ATP efficacy on successfully terminating AT/AF episodes was 39.0% (95% CI: 38.1%–39.9%).

3.5 | Case example

A 48-year-old male was implanted with a Medtronic Protecta XT dual-chamber ICD in February 2012; the device was programmed to MVP mode and rATP was enabled. In April 2013, the patient experienced an AT/AF episode (Figure 4). At onset, the rhythm was AF with a variable cycle length of 160–180 ms. First attempts at ATP failed while the rhythm was very irregular with higher variability in cycle length. After 40 hours and 18 minutes in episode duration, the cycle length slowed...
to 210 ms with the rhythm becoming more regular, and an attempt at ATP was successful at restoring sinus rhythm.

4 | DISCUSSION

In this study, using prospectively acquired data from the deidentified Medtronic CareLink database, 43,440 patients with pacemakers, ICDs, and CRT devices that met eligibility criteria were identified, and rATP therapy was evaluated in an individually matched cohort of 4,016 rATP patients and 4,016 controls. rATP therapy was associated with significant reductions in the risk of having paroxysmal, persistent, and longstanding-persistent AT/AF during 2 years of follow-up. These reductions were consistent in subgroups, and they were independent of whether the patient had a pacemaker, ICD, or CRT device and whether preventive atrial pacing was activated at baseline. Our analysis also indicates reactive ATP is the principal driver of the observed AT/AF risk reductions. To our knowledge, these are the first real-world data on the effectiveness of rATP therapy, and the first data of the therapy in patients with ICD and CRT devices. The data available had the characteristics of "big data," that is, they were related to a large patient sample, although with limited granularity in terms of clinical profile.

Early studies of pacemaker/ICD integrated pacing therapies for AT/AF were promising. Prevention pacing, an atrial overdrive therapy aiming to suppress episode recurrence, was shown in several studies to reduce AT/AF. However, the positive findings from these trials have been overwhelmed by over a dozen studies showing no difference, the latest being the SAFE and ASSERT studies. First-generation atrial ATP therapy was found to be safe and effective at terminating episodes. First-generation atrial ATP therapy was found to be safe and effective at terminating episodes. The latest trial to test pacing therapies for AT/AF, the randomized MINERVA study, was conducted in a selective pacemaker population and demonstrated superiority with prevention pacing plus second-generation atrial ATP (rATP) versus standard pacemaker therapy at reducing the combined endpoint of death, cardiovascular hospitalization, and permanent AF. Results were driven by the effects on AF where the therapy reduced the risk of AT/AF >1 day by 34%, >7 days by 48%, and permanent AF by 61%. Subsequently, AF-related hospitalizations, cardioversions, and emergency room
FIGURE 3  (A and B) Stacked bar charts for the distribution of AT/AF burden within every 30 days in rATP and control groups. Percentages of subjects with different AT/AF burdens sum up to 100% within every 30 days from 30 days before the first transmission (month 0) to 2 years after the first transmission (month 24). AT/AF = atrial tachyarrhythmia; rATP = reactive atrial-based antitachycardia pacing [Color figure can be viewed at wileyonlinelibrary.com]
visits were reduced, suggesting significant cost savings.\textsuperscript{12} These benefits were largely attributed to rATP therapy.\textsuperscript{10,15} One unique aspect of the MINERVA trial was that rather than assessing the efficacy of rATP in terminating single episodes of AT/AF, more clinically valuable arrhythmic endpoints were evaluated, such as prevention of AF episodes of long duration. The novelty of rATP therapy includes the ability to re-deliver ATP when the AT/AF rhythm changes cycle length and/or regularity and to retry ATP therapy over extended durations, with the aim to reduce the burden of AF and the occurrence of AF of longer duration. MINERVA showed that the algorithm was more effective when AT/AF episodes transitioned to slower and more regular rhythms.\textsuperscript{15} Furthermore, data on the reduction of early recurrence of AT/AF and reduction in left atrial diameter suggests reverse electrical and mechanical remodeling of the atria with use of rATP.\textsuperscript{11} These findings compelled us to test the effectiveness of the second-generation ATP algorithm (rATP) in a large population and extend this evaluation to patients with ICDs and CRT devices.

Our findings not only corroborate the results from MINERVA, they suggest that the rATP effects may be equally beneficial regardless of the type of device. This has important implications due to the correlations of AF disease progression with outcomes, especially in patients with a CRT or ICD device who typically have a complex clinical profile that involves left ventricular dysfunction. Chiang et al.'s survey highlighted increased risks of comorbidities as AF progresses,\textsuperscript{3} and a recent meta-analysis of 12 studies containing 99,996 patients reported that nonparoxysmal AF was associated with significant increases in thromboembolism and death.\textsuperscript{23} Recent findings from the ASSERT study reported a strong association between device-detected subclinical AF progression and HF hospitalization.\textsuperscript{24} The CASTLE AF study also reported significant risk reductions in HF hospitalization and/or all-cause death in the ablation arm along with a reduction in AT/AF burden.\textsuperscript{25} By taking into account all of the studies that examined the relationship between type and duration of device-detected AF and risk of stroke, it appears that a dose–response association may exist between AF burden and the subsequent risk of stroke; therefore, reducing AT/AF burden may be indirectly considered as a potentially beneficial endpoint.\textsuperscript{26} Our study included patients with advanced AT/AF as 15% in the matched cohort had at least one persistent or longstanding-persistent episode at baseline, yet rATP was effective immediately and effects persisted throughout the 2-year follow-up. This suggests that use of rATP does not need to be limited to patients with paroxysmal AF only.

### 4.1 Study limitations

The study has its limitations. This was a retrospective study, and similar to other analyses based on "big data," there were uncollected clinical variables that we could not control for that include congestive heart failure, diabetes, hypertension, use of antiarrhythmic drugs, and other therapies for treating AT/AF. However, we controlled for key risk factors at baseline: age, sex, AT/AF, and percentage VP.\textsuperscript{27} Also, we controlled for device type and pacing mode which may relate to the patient’s underlying arrhythmia condition and comorbidity (e.g., heart failure). There is potential for sampling bias as the data is taken from a single-manufacturer’s remote monitoring database largely from patients in the United States. Patients not followed by remote monitoring cannot be accounted for. Finally, patient outcomes such as cardiac function, permanent AF, stroke, and death could not be measured. For example, date of death was not available in the deidentified database either, hence its impact as a potential competing risk on AT/AF incidence could not be determined. Likewise, we did not have data on the use of antiarrhythmic drugs. The MINERVA trial has reported that baseline medications including the use of antiarrhythmic drugs were
similar among the study arms, and patients in the DDDRP+MVP arm that had high reactive ATP efficacy experienced a significant reduction in developing permanent or persistent AF after controlling for antiarrhythmic drugs and other baseline medications. Although we cannot rule out all the potential bias with our data, the fact that the reactive ATP benefit that we observed in this observational study is aligned with the findings from the randomized MINERVA trial is reassuring.

5 | CONCLUSION

In conclusion, among real-world patients from a large database, rATP therapy was associated with a lower rate of AT/AF progression. Therapy effects were independent of whether the patient had a pacemaker, defibrillator, or CRT device.

ACKNOWLEDGMENTS

We would like to thank Andrea Grammatico, PhD, and Eduardo Warman, PhD, from Medtronic for their contributions to the design and technical support of this study. We also thank Professor Luigi Padeletti, MD, in memoriam, for his significant contributions to this field and being the inspiration behind this effort.

DISLOSURES

G.H.C.: Compensation for Services: Boston Scientific Corp., Spectranetics Corporation, Medtronic, plc. Speaker’s Bureau: Spectranetics Corporation. Fellowship Support: Medtronic, plc. Bayer/Schering Pharma, Biotronik, Medtronic. L.P.: Compensation for Services: Bayer/Schering Pharma, Biotronik, Medtronic, plc. S.L.Z.: Compensation for Services: Medtronic, plc. Speaker’s Bureau: Medtronic. Equity Interests/Stock Options – Public: Medtronic, plc. Research Grants: Medtronic, plc. J.H.H.: Equity Interests/Stock Options – Public: Medtronic, plc. Y.Z.: Salary: Medtronic, plc. G.B.: Compensation for Services: Boston Scientific Corp., Medtronic, plc.

ORCID

George H. Crossley MD https://orcid.org/0000-0003-0096-8401
Steven Zweibel MD https://orcid.org/0000-0002-1967-6559
Giuseppe Boriani MD, PhD https://orcid.org/0000-0002-9820-4815

REFERENCES

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147.
2. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes. 2012;5:85-93.
3. Chiang CE, Naditch-Brule L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: Insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632-639.
4. de Bruijn RF, Heeringa J, Wolters FJ, et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015;72:1288-1294.
5. Steinberg BA, Hallkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: Results from the ROCKET-AF Trial. Eur Heart J. 2015;36:288-296.
6. Vermond RA, Geelhoed B, Verweij N, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the Netherlands. J Am Coll Cardiol. 2015;66:1000-1007.
7. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313-320.
8. Mitchell AR, Spurrell PA, Cheatle L, Sulke N. Effect of atrial antitachycardia pacing treatments in patients with an atrial defibrillator: Randomised study comparing subthreshold and nominal pacing outputs. Heart. 2002;87:433-437.
9. Stridh M, Sornmo L, Meurling CJ, Olsson SB. Characterization of atrial fibrillation using the surface ECG: Time-dependent spectral properties. IEEE Trans Biomed Eng. 2001;48:19-27.
10. Boriani G, Tukkie R, Manolis AS, et al. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: The MINERVA randomized multicentre international trial. Eur Heart J. 2014;35:2352-2362.
11. Boriani G, Tukkie R, Biffi M, et al. Atrial antitachycardia pacing and atrial remodeling: A substudy of the international, randomized MINERVA trial. Heart Rhythm. 2014;11:1476-1484.
12. Boriani G, Manolis AS, Tukkie R, et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm. 2015;12:1192-1200.
13. Purerfellner H, Gillis AM, Holbrook R, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol. 2004;27:983-992.
14. Funck RC, Boriani G, Manolis AS, et al. The MINERVA study design and rationale: A controlled randomized trial to assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. Am Heart J. 2008;156:445-451.
15. Padeletti L, Purerfellner H, Mont L, et al. New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial. Heart Rhythm. 2015;12:1717-1725.
16. Carlson MD, Ip J, Messenger J, et al. A new pacemaker algorithm for the treatment of atrial fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003;42:627-633.
17. Garrigue S, Barold SS, Cazeau S, et al. Prevention of atrial arrhythmias during DDD pacing by atrial overdrive. Pacing Clin Electrophysiol. 1998;21:1751-1759.
18. Gold MR, Adler S, Fauchier L, et al. Impact of atrial prevention pacing on atrial fibrillation burden: Primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm. 2009;6:295-301.
19. Hohnloser SH, Healey JS, Gold MR, et al. Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. Heart Rhythm. 2012;9:1667-1673.
20. Lau CP, Tachapong N, Wang CC, et al. Prospective randomized study to assess the efficacy of site and rate of atrial pacing on long-term
progression of atrial fibrillation in sick sinus syndrome: Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) Study. Circulation. 2013;128:687-693.

21. Gold MR, Sulke N, Schwartzman DS, Mehra R, Euler DE, Worldwide Jewel AF-Only Investigators. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001;12:1247-1253.

22. Lee MA, Weachter R, Pollak S, et al. The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: Results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias. J Am Coll Cardiol. 2003;41:1926-1932.

23. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: A systematic review and meta-analysis. Eur Heart J. 2016:1591-1602.

24. Wong JA, Conen D, Van Gelder IC, et al. Progression of device-detected subclinical atrial fibrillation and the risk of heart failure. J Am Coll Cardiol. 2018;71:2603-2611.

25. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-427.

26. Steinberg BA, Piccini JP. When low-risk atrial fibrillation is not so low risk: Beast of burden. JAMA Cardiol. 2018;3:558–560.

27. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. 2019;42:970–979. https://doi.org/10.1111/pace.13696